amantadine has been researched along with Amentia in 18 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study is to compare the occurrence of dementia among Parkinson's disease (PD) patients treated with amantadine (AM group) with those never exposed to it (NoAM group)." | 7.73 | Association between amantadine and the onset of dementia in Parkinson's disease. ( Bonuccelli, U; Ceravolo, R; Inzelberg, R; Klein, C; Logi, C; Miniowich, A; Rabey, JM; Rossi, C; Schechtman, E; Strugatsky, R, 2006) |
| "Thalamic dementia is an uncommon type of stroke that presents with disorientation, behavioral changes, and impairment of executive functions, with relative preservation of motor functions." | 5.62 | Thalamic Dementia in Acute Inpatient Rehabilitation-Role for Amantadine? ( Brentlinger, G; Ghebrendrias, Y; Han, J; Kim, K; Mohan, A; Yeh, BY, 2021) |
| "Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily." | 5.26 | Amantadine in senile dementia: electroencephalographic and clinical effects. ( Boillat, J; Cole, M; Dastoor, DP; Klingner, A; Müller, HF, 1979) |
| " Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium." | 4.79 | Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. ( Camicioli, R; Ganzini, L; Young, BK, 1997) |
| "The objective of this study is to compare the occurrence of dementia among Parkinson's disease (PD) patients treated with amantadine (AM group) with those never exposed to it (NoAM group)." | 3.73 | Association between amantadine and the onset of dementia in Parkinson's disease. ( Bonuccelli, U; Ceravolo, R; Inzelberg, R; Klein, C; Logi, C; Miniowich, A; Rabey, JM; Rossi, C; Schechtman, E; Strugatsky, R, 2006) |
| "Memantine was investigated in a phase II double-blind trial on 30 elderly patients by comparison with a placebo with the aid of several psychometric tests." | 2.66 | Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind study. ( Ambrozi, L; Danielczyk, W, 1988) |
| "Thalamic dementia is an uncommon type of stroke that presents with disorientation, behavioral changes, and impairment of executive functions, with relative preservation of motor functions." | 1.62 | Thalamic Dementia in Acute Inpatient Rehabilitation-Role for Amantadine? ( Brentlinger, G; Ghebrendrias, Y; Han, J; Kim, K; Mohan, A; Yeh, BY, 2021) |
| "Nineteen patients with senile brain disease (including 2 with parkinsonian symptoms) were treated with amantadine in an oral dosage of 200--300 mg daily." | 1.26 | Amantadine in senile dementia: electroencephalographic and clinical effects. ( Boillat, J; Cole, M; Dastoor, DP; Klingner, A; Müller, HF, 1979) |
| " In the antipsychotic classification, special attention is given to side effects (extrapyramidal motor signs, tardive dyskinesias, akathisis) and to dosage for the elderly." | 1.25 | Observations on the psychopharmacology of the aged. ( Eisdorfer, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (55.56) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, K | 1 |
| Mohan, A | 1 |
| Yeh, BY | 1 |
| Ghebrendrias, Y | 1 |
| Brentlinger, G | 1 |
| Han, J | 1 |
| Chang, MC | 1 |
| Wang, F | 1 |
| Feng, TY | 1 |
| Yang, S | 1 |
| Preter, M | 1 |
| Zhou, JN | 1 |
| Wang, XP | 1 |
| Swarztrauber, K | 1 |
| Koudelka, C | 1 |
| Brodsky, MA | 1 |
| Inzelberg, R | 1 |
| Bonuccelli, U | 1 |
| Schechtman, E | 1 |
| Miniowich, A | 1 |
| Strugatsky, R | 1 |
| Ceravolo, R | 1 |
| Logi, C | 1 |
| Rossi, C | 1 |
| Klein, C | 1 |
| Rabey, JM | 1 |
| Allen, RM | 1 |
| Gradner, W | 1 |
| Schnaberth, G | 1 |
| Auff, E | 1 |
| Young, BK | 1 |
| Camicioli, R | 1 |
| Ganzini, L | 1 |
| Eisdorfer, C | 1 |
| Müller, HF | 1 |
| Dastoor, DP | 1 |
| Klingner, A | 1 |
| Cole, M | 1 |
| Boillat, J | 1 |
| Semlitsch, HV | 1 |
| Anderer, P | 1 |
| Saletu, B | 1 |
| Hermesh, H | 1 |
| Sirota, P | 1 |
| Eviatar, J | 1 |
| Sawada, H | 1 |
| Akiguchi, I | 1 |
| Kimura, T | 1 |
| Fukuyama, H | 1 |
| Kameyama, M | 1 |
| Harvey, NS | 1 |
| Otomo, E | 1 |
| Ambrozi, L | 1 |
| Danielczyk, W | 1 |
| Powell, HC | 1 |
| London, GW | 1 |
| Lampert, PW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of a Modified Mindfulness-based Cognitive Therapy for Family Caregivers of People With Dementia in Stress Reduction: A Randomized Controlled Trial[NCT03354819] | 113 participants (Actual) | Interventional | 2017-12-23 | Completed | |||
| Feru-guard (Ferulic Acid and Angelica Archangelica Extract) for Behavioral Symptoms in Dementia[NCT03451760] | Phase 2 | 70 participants (Anticipated) | Interventional | 2018-09-30 | Not yet recruiting | ||
| An Investigation of the Antidepressant Efficacy of Memantine, an NMDA Antagonist With Neurotrophic Properties in Major Depression[NCT00040261] | Phase 3 | 112 participants | Interventional | 2002-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for amantadine and Amentia
| Article | Year |
|---|---|
Drug Therapy for Behavioral and Psychological Symptoms of Dementia.
Topics: Amantadine; Antidepressive Agents; Antipsychotic Agents; Behavioral Symptoms; Cholinesterase Inhibit | 2016 |
Drug Therapy for Behavioral and Psychological Symptoms of Dementia.
Topics: Amantadine; Antidepressive Agents; Antipsychotic Agents; Behavioral Symptoms; Cholinesterase Inhibit | 2016 |
Drug Therapy for Behavioral and Psychological Symptoms of Dementia.
Topics: Amantadine; Antidepressive Agents; Antipsychotic Agents; Behavioral Symptoms; Cholinesterase Inhibit | 2016 |
Drug Therapy for Behavioral and Psychological Symptoms of Dementia.
Topics: Amantadine; Antidepressive Agents; Antipsychotic Agents; Behavioral Symptoms; Cholinesterase Inhibit | 2016 |
Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
Topics: Aging; Akathisia, Drug-Induced; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Cholinergic | 1997 |
Psychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions.
Topics: Amantadine; Antiparkinson Agents; Atrophy; Brain; Bromocriptine; Cognition; Dementia; Dreams; Drug I | 1986 |
2 trials available for amantadine and Amentia
| Article | Year |
|---|---|
Topographic mapping of long latency "cognitive" event-related potentials (P 300): a double-blind, placebo-controlled study with amantadine in mild dementia.
Topics: Aged; Amantadine; Brain; Brain Mapping; Cognition; Dementia; Double-Blind Method; Electrooculography | 1992 |
Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind study.
Topics: Aged; Amantadine; Dementia; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Memantine; N | 1988 |
13 other studies available for amantadine and Amentia
| Article | Year |
|---|---|
Thalamic Dementia in Acute Inpatient Rehabilitation-Role for Amantadine?
Topics: Amantadine; Cerebral Infarction; Dementia; Dopamine Agents; Humans; Male; Middle Aged; Thalamic Nucl | 2021 |
Comments on "Thalamic Dementia in Acute Inpatient Rehabilitation-Role for Amantadine? A Case Report".
Topics: Amantadine; Dementia; Humans; Inpatients; Thalamus | 2021 |
Initial pharmacotherapy in a population of veterans with Parkinson disease.
Topics: Age Factors; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Dat | 2006 |
Association between amantadine and the onset of dementia in Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Comorbidity; Dementia; Female; Humans; Male; Mental Status S | 2006 |
Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
Topics: Adult; Aged; Amantadine; Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Drug Ther | 1982 |
[The Steel Richardson Olszewski-syndrome. A report on 3 further cases (author's transl)].
Topics: Amantadine; Biperiden; Bulbar Palsy, Progressive; Dementia; Dysarthria; Humans; Male; Middle Aged; O | 1981 |
[Dementia--Parkinson disease: role of antiglutamatergic drugs. Symposium: 4 April, Hamburg].
Topics: Amantadine; Antipsychotic Agents; Dementia; Humans; Levodopa; Movement Disorders; Parkinson Disease; | 1998 |
Observations on the psychopharmacology of the aged.
Topics: Aged; Amantadine; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenone | 1975 |
Amantadine in senile dementia: electroencephalographic and clinical effects.
Topics: Administration, Oral; Aged; Amantadine; Anxiety; Dementia; Depression; Electroencephalography; Femal | 1979 |
Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine.
Topics: Aged; Amantadine; Dementia; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Malign | 1989 |
[A case of venous dural sinus thrombosis presenting dementia syndrome. An autopsy case].
Topics: Amantadine; Brain; Calcinosis; Dementia; Humans; Male; Middle Aged; Sinus Thrombosis, Intracranial | 1989 |
[Drug therapy of Alzheimer's disease. General concepts on nootropic drugs].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amantadine; Aminoacridines; Dementia; gamma-Aminobutyric | 1988 |
Neurofibrillary tangles in progressive supranuclear palsy. Electron microscopic observations.
Topics: Aged; Amantadine; Brain; Brain Diseases; Bulbar Palsy, Progressive; Dementia; Dihydroxyphenylalanine | 1974 |